These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24454706)

  • 1. Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis.
    Ditkowsky JB; Schwartzman K
    PLoS One; 2014; 9(1):e83526. PubMed ID: 24454706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
    Tseng CL; Oxlade O; Menzies D; Aspler A; Schwartzman K
    BMC Public Health; 2011 Jan; 11():55. PubMed ID: 21269503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa.
    Channing L; Sinanovic E
    Cost Eff Resour Alloc; 2014; 12():20. PubMed ID: 25242892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis.
    Abubakar I; Pimpin L; Ariti C; Beynon R; Mangtani P; Sterne JA; Fine PE; Smith PG; Lipman M; Elliman D; Watson JM; Drumright LN; Whiting PF; Vynnycky E; Rodrigues LC
    Health Technol Assess; 2013 Sep; 17(37):1-372, v-vi. PubMed ID: 24021245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
    Dye C
    J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
    Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
    Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.
    Tanner R; Kakalacheva K; Miller E; Pathan AA; Chalk R; Sander CR; Scriba T; Tameris M; Hawkridge T; Mahomed H; Hussey G; Hanekom W; Checkley A; McShane H; Fletcher HA
    BMC Infect Dis; 2014 Dec; 14():660. PubMed ID: 25466778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of universal BCG vaccination of Japanese infants.
    Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
    Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
    Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
    Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
    Fu H; Lin HH; Hallett TB; Arinaminpathy N
    Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Evaluation of Selective Neonatal Bacillus Calmette-Guérin Vaccination of High-risk Infants in Ireland.
    Teljeur C; Moran PS; Harrington P; Butler K; Corcoran B; O'Donnell J; Usher C; O'Flanagan D; Connolly K; Ryan M
    Pediatr Infect Dis J; 2018 Aug; 37(8):759-767. PubMed ID: 29432385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.
    Colditz GA; Berkey CS; Mosteller F; Brewer TF; Wilson ME; Burdick E; Fineberg HV
    Pediatrics; 1995 Jul; 96(1 Pt 1):29-35. PubMed ID: 7596718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer.
    Bachir BG; Dragomir A; Aprikian AG; Tanguay S; Fairey A; Kulkarni GS; Breau RH; Black PC; Kassouf W
    Cancer; 2014 Aug; 120(16):2424-31. PubMed ID: 24752448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us?
    Menzies D
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S71-4. PubMed ID: 11010826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The real-life number of neonatal doses of Bacille Calmette-Guérin vaccine in a 20-dose vial.
    Schaltz-Buchholzer F; Frankel HN; Benn CS
    Glob Health Action; 2017; 10(1):1-4. PubMed ID: 28169606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
    Hawkridge T; Scriba TJ; Gelderbloem S; Smit E; Tameris M; Moyo S; Lang T; Veldsman A; Hatherill M; Merwe Lv; Fletcher HA; Mahomed H; Hill AV; Hanekom WA; Hussey GD; McShane H
    J Infect Dis; 2008 Aug; 198(4):544-52. PubMed ID: 18582195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial.
    Ritz N; Dutta B; Donath S; Casalaz D; Connell TG; Tebruegge M; Robins-Browne R; Hanekom WA; Britton WJ; Curtis N
    Am J Respir Crit Care Med; 2012 Jan; 185(2):213-22. PubMed ID: 22071384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial.
    Jensen SK; Jensen TM; Birk NM; Stensballe LG; Benn CS; Jensen KJ; Pryds O; Jeppesen DL; Nissen TN
    Vaccine; 2020 Mar; 38(11):2449-2455. PubMed ID: 32057570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study.
    Fack C; Wood R; Hatherill M; Cobelens F; Hermans S
    Vaccine; 2022 Jan; 40(2):364-369. PubMed ID: 34872798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?
    Moliva JI; Turner J; Torrelles JB
    Vaccine; 2015 Sep; 33(39):5035-41. PubMed ID: 26319069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.